Population Pharmacokinetics of BMN 673, a Novel PARP Inhibitor, in Beagle Dogs

被引：0
|
作者：
Qi, Yulan [1 ]
Musson, Don [1 ]
Tsuruda, Laurie [1 ]
Zhou, Huiyu [1 ]
Cheng, Alphonsus [1 ]
O'Neill, Charles [1 ]
机构：
[1] BioMarin Pharmaceut Inc, Novato, CA 94949 USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2013年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S30 / S30
页数：1
相关论文
共 50 条
  • [1] Selective sensitivity of Ewing's Sarcoma to the PARP inhibitor BMN 673
    Singh, Arun
    Chmielowski, Bartosz
    Jia, Weiping
    Clarke, Kareem
    O'Brien, Neil
    Dering, Judy
    Conklin, Dylan
    Shen, Yuqiao
    Post, Leonard
    Finn, Richard S.
    Slamon, Dennis J.
    [J]. CANCER RESEARCH, 2013, 73 (08)
  • [2] Inhibition of PBMC PARP activity with the novel PARP 1/2 inhibitor BMN 673 in patients with advanced solid tumors
    Henshaw, Joshua W.
    Zhou, Huiyu
    Herriott, Ashleigh
    Patterson, Miranda
    Wang, Evelyn W.
    Musson, Don
    de Bono, Johann
    Mina, Lida A.
    Ramanathan, Ramesh K.
    O'Neill, Charles
    Dorr, Andrew
    Curtin, Nicola J.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [3] First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.
    De Bono, Johann Sebastian
    Mina, Lida A.
    Gonzalez, Michael
    Curtin, Nicola J.
    Wang, Evelyn
    Henshaw, Joshua W.
    Chadha, Manpreet
    Sachdev, Jasgit C.
    Matei, Daniela
    Jameson, Gayle S.
    Ong, Michael
    Basu, Bristi
    Wainberg, Zev A.
    Byers, Lauren Averett
    Chugh, Rashmi
    Dorr, Andrew
    Kaye, Stanley B.
    Ramanathan, Ramesh K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Update on first-in-man trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors
    Wainberg, Zev A.
    de Bono, Johann S.
    Mina, Lida
    Sachdev, Jasgit
    Byers, Lauren Averett
    Chugh, Rashmi
    Zhang, Charlie
    Henshaw, Joshua W.
    Dorr, Andrew
    Glaspy, John
    Ramanathan, Ramesh
    [J]. MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [5] The effect of food on the oral bioavailability of the novel PARP 1/2 inhibitor BMN 673 in healthy male subjects
    Henshaw, Joshua
    Zhou, Huiyu
    Musson, Don
    O'Neill, Charles
    Stoltz, Randall
    Dorr, Andrew
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [6] BMN-673 Poly [ADP-ribose] Polymerase (PARP) Inhibitor Oncolytic
    Gras, Jordi
    [J]. DRUGS OF THE FUTURE, 2013, 38 (12) : 813 - 819
  • [7] BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy
    Soni, Aashish
    Lin, Xixi
    Mladenov, Emil
    Mladenova, Veronika
    Stuschke, Martin
    Iliakis, George
    [J]. CANCERS, 2022, 14 (22)
  • [8] IN-VIVO METABOLISM AND DISPOSITION OF A NEW ANTICANCER PARP INHIBITOR BMN 673 IN RAT AND DOG
    Musson, Donald
    Musson, Donald G.
    Haroldsen, Peter
    Oppeneer, Todd
    Bashir, Mohammed
    O'Neill, Charles
    [J]. DRUG METABOLISM REVIEWS, 2012, 44 : 126 - 127
  • [9] Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer
    Wilkerson, Paul M.
    Dedes, Konstantin J.
    Samartzis, Eleftherios Pierre
    Dedes, Ioannis
    Lambros, Maryou B.
    Natrajan, Rachael
    Gauthier, Arnaud
    Piscuoglio, Salvatore
    Topfer, Chantal
    Vukovic, Vesna
    Daley, Frances
    Weigelt, Britta
    Reis-Filho, Jorge S.
    [J]. ONCOTARGET, 2017, 8 (04) : 6057 - 6066
  • [10] Nanoformulations of the PARP inhibitors olaparib and BMN 673 for cancer nanotherapy
    Sridhar, S.
    Tangutoori, S.
    Baldwin, P.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : 116 - 116
12345